Latest Content

Oncology nurse Diane Stanaway offers essential sun protection strategies as NJ prepares for the heat of the 2026 World Cup and rising skin cancer rates.

The FDA approved the BESREMi Pen for polycythemia vera, offering a simplified self-administration option to improve patient adherence and care.

Rita M. Jakubowski, NP, explains how multidisciplinary age-friendly assessments and the CHARM study improve outcomes for older transplant patients.

Dr. Sonja J. Hughes discusses managing GI toxicities and the need for research regarding GLP-1 use among breast cancer patients and survivors.

Diane Stanaway, MSN, RN, highlights the importance of long-term skin protection for oncology patients during high-exposure events like the World Cup.

Nicholas Hornstein, MD, PhD discusses ctDNA in colorectal cancer, the INTERCEPT-TT trial, building Northwell's GI oncology program, and what better drugs will look like.

FDA approves sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of advanced triple-negative breast cancer.

The FDA approved palbociclib (Ibrance) for maintenance in HR+/HER2+ metastatic breast cancer after induction therapy, based on the PATINA trial.

Dr. Sriram Machineni explains why GLP-1 medications help manage cardiovascular health and inflammation in breast cancer survivorship.

Teddi Mellencamp highlights the vital bond and advocacy of oncology nurses during the 2026 Extraordinary Healer awards ceremony in San Antonio.

Oncology nurses can guide patients through the rationale and implications of this decision.

Christina Klawitter, MSN, RN, OCN, discusses how meticulous pre-planning and team delegation optimize safety and patient care in clinical trials.

Dr. Morvarid Rezaie discusses how oncology nurses can leverage medical cannabis to address polypharmacy and enhance opioid synergy for symptom control.